External validation and calibration of the <scp>HoLISTIC</scp> Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐<scp>HIPI</scp>) in the Brazilian Hodgkin lymphoma registry
The Hodgkin lymphoma International Study for Individual Care (HoLISTIC) Consortium's A-HIPI model, developed in 2022 for advanced-stage classical Hodgkin lymphoma (cHL), predicts survival within 5 years amongst newly diagnosed patients. This study validates its performance in the Brazilian Hodgkin lymphoma registry. By 2022, the Brazilian HL registry included 1357 cHL patients, with a median 5-year follow-up. Probabilities for 5-year progression-free survival (PFS) and overall survival (OS) were calculated using A-HIPI-model equations. Discrimination (Harrell C-statistic/Uno C-statistic) and calibration measures assessed external validation and calibration. Lab values beyond the allowed range were excluded, mirroring the initial A-HIPI analysis. A total of 694 advanced-stage cHL patients met the original inclusion criteria (age 18-65 years, Stage IIB-IV). Median age was 31 years; 46.3% were females. Stage distribution was IIB (33.1%), III (27.4%), IV (39.5%). Bulky disease in 32.6%. Five-year PFS and OS were 68.4% and 86.0%, respectively. Harrell C-statistics were 0.60 for PFS and 0.69 for OS, and Uno C-statistics were 0.63 for PFS and 0.72 for OS. Calibration plots demonstrated well-calibrated predictions with calibration slopes of 0.91 and 1.03 for 5-year OS and PFS, respectively. Despite differing patient, clinical characteristics, and socioeconomic factors, the baseline prediction tool performed well in the Brazilian cohort, demonstrating adequate discrimination and calibration. This supports its reliability in diverse settings.
Authors
- Susan K. Parsons (ORCID: https://orcid.org/0000-0003-0282-6490)
- Talita Silveira (ORCID: https://orcid.org/0000-0002-6367-7516)
- Valéria Buccheri (ORCID: https://orcid.org/0000-0002-6999-4109)
- Andy Evans (ORCID: https://orcid.org/0000-0002-3320-0215)
- Carolina Colaço Villarim
- Leila Perobelli (ORCID: https://orcid.org/0000-0002-0643-5975)
- R Silva (ORCID: https://orcid.org/0000-0003-2804-5414)
- Carla Boquimpani (ORCID: https://orcid.org/0000-0001-7396-2495)
- Rafael Dezen Gaiolla (ORCID: https://orcid.org/0000-0002-9480-4995)
- Kátia Bórgia Barbosa Pagnano (ORCID: https://orcid.org/0000-0001-7975-0805)
- Frederico Rafael Moreira (ORCID: https://orcid.org/0000-0001-5747-001X)
- Fabı́ola Traina (ORCID: https://orcid.org/0000-0003-4258-289X)
- Irène Biasoli (ORCID: https://orcid.org/0000-0001-7265-7691)
- Caroline Sola (ORCID: https://orcid.org/0000-0002-2643-2405)
- Cármino Antônio De Souza (ORCID: https://orcid.org/0000-0001-8656-8374)
- Monica Praxedes
- Ana Carolina Ribas
- Cristiana Solza (ORCID: https://orcid.org/0000-0002-4543-3630)
- Giovanna Steffenello
- Angie Mae Rodday (ORCID: https://orcid.org/0000-0002-8671-3401)
- Nelson Castro (ORCID: https://orcid.org/0000-0002-5084-9083)
- Otávio Baiocchi
- Nelson Spector (ORCID: https://orcid.org/0000-0002-2733-9835)
Institutions
- Rutgers, The State University of New Jersey (US)
- Universidade Federal de Minas Gerais (BR)
- Universidade Federal do Rio de Janeiro (BR)
- Universidade de Ribeirão Preto (BR)
- Universidade Federal Fluminense (BR)
- Universidade de São Paulo (BR)
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Universidade do Estado do Rio de Janeiro (BR)
- Universidade Federal de Santa Catarina (BR)
- Hemorio (BR)
- Instituto do Câncer do Estado de São Paulo (BR)
- Hospital de Câncer de Barretos (BR)
- Baim Institute for Clinical Research (US)
- Dr. Euryclides Hospital de Jesus Zerbini (BR)
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
- Centro de Pesquisas Oncológicas (BR)
- Universidade Federal do Paraná (BR)
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1111/bjh.19824
- Citations
- 2
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Pfizer
- Incyte
- Seagen
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Faculdade de Medicina da Universidade de São Paulo
- Genentech
- Pharmacyclics
- National Cancer Institute
- Daiichi Sankyo Europe